Antoine F Carpentier Selected Research

CPG-oligonucleotide

1/2017	Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
9/2015	Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.
1/2012	Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.
4/2010	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.
9/2008	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses.
5/2008	Expression of TLR9 within human glioblastoma.
1/2006	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
10/2005	Successful combination of local CpG-ODN and radiotherapy in malignant glioma.
1/2005	[Cancer immunotherapy with CpG-ODN].
1/2003	CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antoine F Carpentier Research Topics

Disease

29	Neoplasms (Cancer) 04/2022 - 07/2002
18	Glioblastoma (Glioblastoma Multiforme) 04/2022 - 04/2005
13	Glioma (Gliomas) 12/2021 - 01/2003
5	Brain Neoplasms (Brain Tumor) 05/2014 - 03/2009
3	Melanoma (Melanoma, Malignant) 09/2020 - 02/2004
3	Disease Progression 01/2020 - 05/2014
3	Fever (Fevers) 01/2017 - 01/2006
3	Lymphopenia (Lymphocytopenia) 09/2015 - 01/2006
2	Infections 09/2021 - 01/2005
2	Meningitis 01/2020 - 09/2015
2	Edema (Dropsy) 03/2016 - 04/2011
2	Colorectal Neoplasms (Colorectal Cancer) 05/2014 - 01/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2021
1	Febrile Neutropenia 10/2021
1	COVID-19 09/2021
1	Cytokine Release Syndrome 11/2020
1	Neoplasm Metastasis (Metastasis) 09/2020
1	Nervous System Diseases (Neurological Disorders) 01/2020
1	Myasthenia Gravis 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Squamous Cell Carcinoma of Head and Neck 07/2016
1	Hypertension (High Blood Pressure) 03/2016
1	Neutropenia 09/2015
1	Erythema 09/2015
1	Anemia 09/2015
1	Breast Neoplasms (Breast Cancer) 05/2014
1	Body Weight (Weight, Body) 02/2014
1	Colonic Neoplasms (Colon Cancer) 01/2013
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2013
1	Adenocarcinoma of Lung 04/2012
1	Hemorrhage 03/2012
1	Cardiomyopathies (Cardiomyopathy) 03/2012

Drug/Important Bio-Agent (IBA)

11	CPG-oligonucleotideIBA 01/2017 - 07/2002
9	Bevacizumab (Avastin)FDA Link 01/2022 - 01/2013
8	AntigensIBA 03/2021 - 01/2003
7	Temozolomide (Temodar)FDA LinkGeneric 04/2022 - 05/2007
7	VaccinesIBA 03/2021 - 11/2003
7	OligodeoxyribonucleotidesIBA 01/2017 - 07/2002
6	Lomustine (CCNU)FDA Link 01/2019 - 06/2006
4	SteroidsIBA 01/2020 - 10/2010
4	OligonucleotidesIBA 05/2008 - 01/2003
3	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2019
3	Pharmaceutical PreparationsIBA 10/2021 - 01/2006
3	LigandsIBA 01/2020 - 09/2008
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2014 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2017
2	Cancer VaccinesIBA 03/2021 - 01/2017
2	Melanins (Melanin)IBA 03/2021 - 12/2020
2	Chimeric Antigen ReceptorsIBA 01/2021 - 11/2020
2	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2017 - 01/2016
2	LY-2157299IBA 05/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 05/2017 - 01/2016
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2017 - 01/2005
2	DNA (Deoxyribonucleic Acid)IBA 07/2016 - 11/2003
2	Tyrosine Kinase InhibitorsIBA 01/2014 - 01/2013
2	Monoclonal AntibodiesIBA 01/2013 - 01/2005
2	ErbB Receptors (EGF Receptor)IBA 03/2009 - 08/2005
1	NivolumabIBA 04/2022
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Gemcitabine FDA Link 12/2021
1	Cisplatin (Platino)FDA LinkGeneric 12/2021
1	Antineoplastic Agents (Antineoplastics)IBA 12/2021
1	LY3300054IBA 12/2021
1	130-nm albumin-bound paclitaxelIBA 12/2021
1	Azacitidine (5 Azacytidine)FDA Link 10/2021
1	eprenetapoptIBA 10/2021
1	EpitopesIBA 12/2020
1	OvalbuminIBA 12/2020
1	incomplete Freund's adjuvantIBA 12/2020
1	Protein Subunit VaccinesIBA 12/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2019
1	pembrolizumabIBA 01/2019
1	Chemokine CCL22IBA 05/2017
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 05/2017
1	Glial Fibrillary Acidic ProteinIBA 05/2017
1	CytosineIBA 01/2017
1	TG4010IBA 01/2017
1	GuanosineIBA 01/2017
1	Interleukin-2 (IL2)IBA 01/2017
1	Oncogene Proteins (Oncogene Protein)IBA 07/2016
1	Indicators and Reagents (Reagents)IBA 07/2016
1	Angiotensin Receptor AntagonistsIBA 03/2016
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2014
1	Carisoprodol (Soma)FDA LinkGeneric 05/2012
1	Pemetrexed (MTA)FDA Link 04/2012
1	Carboplatin (JM8)FDA LinkGeneric 04/2012

Therapy/Procedure

17	Therapeutics 12/2021 - 11/2003
9	Radiotherapy 04/2022 - 01/2003
8	Drug Therapy (Chemotherapy) 09/2021 - 01/2003
5	Immunotherapy 09/2020 - 01/2003
2	Subcutaneous Injections 01/2017 - 09/2015
2	Injections 01/2003 - 07/2002
1	Drug Tapering 10/2021
1	Artificial Respiration (Mechanical Ventilation) 09/2021
1	Photothermal Therapy 03/2021